Clinical benefit of COX-2 inhibitors in the adjuvant chemotherapy of advanced non-small cell lung cancer: A systematic review and metaanalysis

作     者：Yu-Qiong Xu Xiang Long Ming Han Ming-Qiang Huang Jia-Fa Lu Xue-Dong Sun Wei Han 

作者机构：Department of Emergency MedicineShenzhen University General HospitalShenzhen University Clinical Medical AcademyShenzhen 518000Guangdong ProvinceChina Department of Respiratory and Critical Care MedicinePeking University Shenzhen HospitalShenzhen 518000Guangdong ProvinceChina 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2021年第9卷第3期

页      面：581-601页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：The Sanming Project of Medicine in Shenzhen No.SZSM201911007 

主　　题：Non-small cell lung cancer COX-2 Survival Progression free survival Systematic review Randomized controlled trials 

摘      要：BACKGROUND Lung cancer is a major cause of death among patients,and non-small cell lung cancer(NSCLC)accounts for more than 80%of all lung cancers in many *** To evaluate the clinical benefit(CB)of COX-2 inhibitors in patients with advanced NSCLC using systematic *** We searched the six electronic databases up until December 9,2019 for studies that examined the efficacy and safety of the addition of COX-2 inhibitors to chemotherapy for *** survival(OS),progression free survival(PFS),1-year survival rate(SR),overall response rate(ORR),CB,complete response(CR),partial response(PR),stable disease(SD),and toxicities were measured with more than one outcome as their *** and random effects models were used to calculate risk estimates in a *** publication bias was calculated using Egger’s linear regression *** analysis was performed using R *** The COX-2 inhibitors combined with chemotherapy were not found to be more effective than chemotherapy alone in OS,progression free survival,1-year SR,CB,CR,and ***,there was a difference in overall response rate for patients with advanced *** a subgroup analysis,significantly increased ORR results were found for celecoxib,rofecoxib,first-line treatment,and *** adverse events,the increase in COX-2 inhibitor was positively correlated with the increase in grade 3 and 4 toxicity of leukopenia,thrombocytopenia,and cardiovascular *** COX-2 inhibitor combined with chemotherapy increased the total effective rate of advanced NSCLC with the possible increased risk of blood toxicity and cardiovascular events and had no effect on survival index.